News Releases
Oct 21, 2021
ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia Read more
Oct 7, 2021
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio Read more
Oct 5, 2021
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors Read more
Oct 1, 2021
ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Read more
Sep 16, 2021
ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma Read more
Sep 7, 2021
ALX Oncology Announces Upcoming Virtual Investor Conference Participation Read more
Aug 12, 2021
ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Read more
Jul 28, 2021
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma Read more
Jul 3, 2021
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer Read more
Jun 14, 2021
ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies Read more